Skip to main content

ZYUS Life Sciences Announces Closing of First Tranche of Unit Offering

Newswire.ca - Tue Jul 29, 2025

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

SASKATOON, SK, July 29, 2025 /CNW/ - ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce that it has now completed a first tranche (the "First Tranche") of its non-brokered private placement (the "Offering") of up to 1,408,450 units (each a "Unit") for up to CAD $1,000,000. Under the First Tranche of the Offering, 450,281 Units were issued at a price of $0.71 per Unit for gross proceeds of approximately $319,700.

Read more at newswire.ca

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.